CytoGenix and Aldevron Announce Positive Results of synDNA Hepatitis Vaccine Stu

[Guest guest]

CytoGenix and Aldevron Announce Positive Results of synDNA Hepatitis Vaccine

Study

12/19/05 -- CytoGenix, Inc. (OTCBB:CYGX) and Aldevron, LLC announced

positive results of a pilot study using CytoGenix synDNA as the active

ingredient in a Hepatitis B vaccine, demonstrating that it is highly

effective in generating an immune response.

DNA vaccines are comprised of genes that confer immunologic protection by

producing antigens without the need to expose the body to pathogenic

organisms. For this study, CytoGenix scientists prepared a synthetic DNA

vaccine derived from a plasmid provided by Aldevron that produces a

Hepatitis B viral surface antigen. Aldevron's scientists tested CytoGenix

synDNA vaccine's activity in a rabbit model using Aldevron's proprietary

Genetic Immunization and Antibody (GIA) technology.

Aldevron scientists compared levels of gene-specific serum immunoglobulin

produced by the synDNA vaccine to its traditional plasmid DNA vaccine.

The synDNA vaccine generated immunoglobulin levels in the test animals

up to five times greater than a comparable plasmid DNA vaccine produced by

bacterial fermentation.

Vazquez, CytoGenix, Inc.'s Executive Vice President and COO,

commented, " These results are very important because they confirm the

effectiveness of synDNA that we have seen in other animal studies of DNA

vaccines. It is clear that our synDNA process produces bio-active DNA.

This latest result is a major step forward in our efforts to accelerate

CytoGenix' Rapid Response Vaccine Development Program against H5N1 avian

flu, smallpox and other infectious disease targets. "

Chambers, Aldevron President and CEO, stated, " Aldevron has

supported the DNA vaccine field for the past seven years by providing

quality DNA, antibody and protein products as well as by sponsoring

scientific forums and maintaining the DNAvaccine.com web site. The

synDNA process is potentially a big step forward in the DNA vaccine and

gene medicine fields. We look forward to expanding Aldevron-CytoGenix

scientific and business collaboration. "

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical

company that develops and markets innovative products and services based on

its proprietary ssDNA expression technology. The company has developed a

breakthrough synthetic process for large-scale production of high purity DNA

at a fraction of the cost of traditional fermentation methods. CytoGenix

currently has one issued US patent and 41 international or US pending patent

applications claiming methods and materials in connection with this platform

technology.

About Aldevron: With facilities in the United States and Europe, Aldevron

offers products and services to DNA vaccine and gene therapy scientists.

These include contract bio-manufacturing, genetic immunization and antibody

production, and a complete line of gene therapy plasmids. More information

can be found at http://www.aldevron.com.

SAFE HARBOR: Except for statements of historical fact, the statements in

this press release are forward-looking. Such statements are subject to a

number of risks and uncertainties that could cause actual results to differ

materially from the statements made. These factors include, but are not

limited to, general economic conditions, risks associated with the

acceptance of new products, competition, and other factors more fully

detailed in the company's filings with the Securities and Exchange

Commission.

Additional information about CytoGenix and its technology can be found on

the website at www.cytogenix.com.

Source: CytoGenix, Inc.

http://www.bio.com/industryanalysis/industryanalysis_news.jhtml?cid=15600029

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

CytoGenix and Aldevron Announce Positive Results of synDNA Hepatitis Vaccine

Study

12/19/05 -- CytoGenix, Inc. (OTCBB:CYGX) and Aldevron, LLC announced

positive results of a pilot study using CytoGenix synDNA as the active

ingredient in a Hepatitis B vaccine, demonstrating that it is highly

effective in generating an immune response.

DNA vaccines are comprised of genes that confer immunologic protection by

producing antigens without the need to expose the body to pathogenic

organisms. For this study, CytoGenix scientists prepared a synthetic DNA

vaccine derived from a plasmid provided by Aldevron that produces a

Hepatitis B viral surface antigen. Aldevron's scientists tested CytoGenix

synDNA vaccine's activity in a rabbit model using Aldevron's proprietary

Genetic Immunization and Antibody (GIA) technology.

Aldevron scientists compared levels of gene-specific serum immunoglobulin

produced by the synDNA vaccine to its traditional plasmid DNA vaccine.

The synDNA vaccine generated immunoglobulin levels in the test animals

up to five times greater than a comparable plasmid DNA vaccine produced by

bacterial fermentation.

Vazquez, CytoGenix, Inc.'s Executive Vice President and COO,

commented, " These results are very important because they confirm the

effectiveness of synDNA that we have seen in other animal studies of DNA

vaccines. It is clear that our synDNA process produces bio-active DNA.

This latest result is a major step forward in our efforts to accelerate

CytoGenix' Rapid Response Vaccine Development Program against H5N1 avian

flu, smallpox and other infectious disease targets. "

Chambers, Aldevron President and CEO, stated, " Aldevron has

supported the DNA vaccine field for the past seven years by providing

quality DNA, antibody and protein products as well as by sponsoring

scientific forums and maintaining the DNAvaccine.com web site. The

synDNA process is potentially a big step forward in the DNA vaccine and

gene medicine fields. We look forward to expanding Aldevron-CytoGenix

scientific and business collaboration. "

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical

company that develops and markets innovative products and services based on

its proprietary ssDNA expression technology. The company has developed a

breakthrough synthetic process for large-scale production of high purity DNA

at a fraction of the cost of traditional fermentation methods. CytoGenix

currently has one issued US patent and 41 international or US pending patent

applications claiming methods and materials in connection with this platform

technology.

About Aldevron: With facilities in the United States and Europe, Aldevron

offers products and services to DNA vaccine and gene therapy scientists.

These include contract bio-manufacturing, genetic immunization and antibody

production, and a complete line of gene therapy plasmids. More information

can be found at http://www.aldevron.com.

SAFE HARBOR: Except for statements of historical fact, the statements in

this press release are forward-looking. Such statements are subject to a

number of risks and uncertainties that could cause actual results to differ

materially from the statements made. These factors include, but are not

limited to, general economic conditions, risks associated with the

acceptance of new products, competition, and other factors more fully

detailed in the company's filings with the Securities and Exchange

Commission.

Additional information about CytoGenix and its technology can be found on

the website at www.cytogenix.com.

Source: CytoGenix, Inc.

http://www.bio.com/industryanalysis/industryanalysis_news.jhtml?cid=15600029

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

CytoGenix and Aldevron Announce Positive Results of synDNA Hepatitis Vaccine

Study

12/19/05 -- CytoGenix, Inc. (OTCBB:CYGX) and Aldevron, LLC announced

positive results of a pilot study using CytoGenix synDNA as the active

ingredient in a Hepatitis B vaccine, demonstrating that it is highly

effective in generating an immune response.

DNA vaccines are comprised of genes that confer immunologic protection by

producing antigens without the need to expose the body to pathogenic

organisms. For this study, CytoGenix scientists prepared a synthetic DNA

vaccine derived from a plasmid provided by Aldevron that produces a

Hepatitis B viral surface antigen. Aldevron's scientists tested CytoGenix

synDNA vaccine's activity in a rabbit model using Aldevron's proprietary

Genetic Immunization and Antibody (GIA) technology.

Aldevron scientists compared levels of gene-specific serum immunoglobulin

produced by the synDNA vaccine to its traditional plasmid DNA vaccine.

The synDNA vaccine generated immunoglobulin levels in the test animals

up to five times greater than a comparable plasmid DNA vaccine produced by

bacterial fermentation.

Vazquez, CytoGenix, Inc.'s Executive Vice President and COO,

commented, " These results are very important because they confirm the

effectiveness of synDNA that we have seen in other animal studies of DNA

vaccines. It is clear that our synDNA process produces bio-active DNA.

This latest result is a major step forward in our efforts to accelerate

CytoGenix' Rapid Response Vaccine Development Program against H5N1 avian

flu, smallpox and other infectious disease targets. "

Chambers, Aldevron President and CEO, stated, " Aldevron has

supported the DNA vaccine field for the past seven years by providing

quality DNA, antibody and protein products as well as by sponsoring

scientific forums and maintaining the DNAvaccine.com web site. The

synDNA process is potentially a big step forward in the DNA vaccine and

gene medicine fields. We look forward to expanding Aldevron-CytoGenix

scientific and business collaboration. "

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical

company that develops and markets innovative products and services based on

its proprietary ssDNA expression technology. The company has developed a

breakthrough synthetic process for large-scale production of high purity DNA

at a fraction of the cost of traditional fermentation methods. CytoGenix

currently has one issued US patent and 41 international or US pending patent

applications claiming methods and materials in connection with this platform

technology.

About Aldevron: With facilities in the United States and Europe, Aldevron

offers products and services to DNA vaccine and gene therapy scientists.

These include contract bio-manufacturing, genetic immunization and antibody

production, and a complete line of gene therapy plasmids. More information

can be found at http://www.aldevron.com.

SAFE HARBOR: Except for statements of historical fact, the statements in

this press release are forward-looking. Such statements are subject to a

number of risks and uncertainties that could cause actual results to differ

materially from the statements made. These factors include, but are not

limited to, general economic conditions, risks associated with the

acceptance of new products, competition, and other factors more fully

detailed in the company's filings with the Securities and Exchange

Commission.

Additional information about CytoGenix and its technology can be found on

the website at www.cytogenix.com.

Source: CytoGenix, Inc.

http://www.bio.com/industryanalysis/industryanalysis_news.jhtml?cid=15600029

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

CytoGenix and Aldevron Announce Positive Results of synDNA Hepatitis Vaccine

Study

12/19/05 -- CytoGenix, Inc. (OTCBB:CYGX) and Aldevron, LLC announced

positive results of a pilot study using CytoGenix synDNA as the active

ingredient in a Hepatitis B vaccine, demonstrating that it is highly

effective in generating an immune response.

DNA vaccines are comprised of genes that confer immunologic protection by

producing antigens without the need to expose the body to pathogenic

organisms. For this study, CytoGenix scientists prepared a synthetic DNA

vaccine derived from a plasmid provided by Aldevron that produces a

Hepatitis B viral surface antigen. Aldevron's scientists tested CytoGenix

synDNA vaccine's activity in a rabbit model using Aldevron's proprietary

Genetic Immunization and Antibody (GIA) technology.

Aldevron scientists compared levels of gene-specific serum immunoglobulin

produced by the synDNA vaccine to its traditional plasmid DNA vaccine.

The synDNA vaccine generated immunoglobulin levels in the test animals

up to five times greater than a comparable plasmid DNA vaccine produced by

bacterial fermentation.

Vazquez, CytoGenix, Inc.'s Executive Vice President and COO,

commented, " These results are very important because they confirm the

effectiveness of synDNA that we have seen in other animal studies of DNA

vaccines. It is clear that our synDNA process produces bio-active DNA.

This latest result is a major step forward in our efforts to accelerate

CytoGenix' Rapid Response Vaccine Development Program against H5N1 avian

flu, smallpox and other infectious disease targets. "

Chambers, Aldevron President and CEO, stated, " Aldevron has

supported the DNA vaccine field for the past seven years by providing

quality DNA, antibody and protein products as well as by sponsoring

scientific forums and maintaining the DNAvaccine.com web site. The

synDNA process is potentially a big step forward in the DNA vaccine and

gene medicine fields. We look forward to expanding Aldevron-CytoGenix

scientific and business collaboration. "

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical

company that develops and markets innovative products and services based on

its proprietary ssDNA expression technology. The company has developed a

breakthrough synthetic process for large-scale production of high purity DNA

at a fraction of the cost of traditional fermentation methods. CytoGenix

currently has one issued US patent and 41 international or US pending patent

applications claiming methods and materials in connection with this platform

technology.

About Aldevron: With facilities in the United States and Europe, Aldevron

offers products and services to DNA vaccine and gene therapy scientists.

These include contract bio-manufacturing, genetic immunization and antibody

production, and a complete line of gene therapy plasmids. More information

can be found at http://www.aldevron.com.

SAFE HARBOR: Except for statements of historical fact, the statements in

this press release are forward-looking. Such statements are subject to a

number of risks and uncertainties that could cause actual results to differ

materially from the statements made. These factors include, but are not

limited to, general economic conditions, risks associated with the

acceptance of new products, competition, and other factors more fully

detailed in the company's filings with the Securities and Exchange

Commission.

Additional information about CytoGenix and its technology can be found on

the website at www.cytogenix.com.

Source: CytoGenix, Inc.

http://www.bio.com/industryanalysis/industryanalysis_news.jhtml?cid=15600029

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/